MDMA vs Psilocin
A side-by-side research comparison of MDMA and Psilocin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | MDMA | Psilocin |
|---|---|---|
| Full name | 3,4-Methylenedioxymethamphetamine | 4-Hydroxy-DMT (active form of psilocybin) |
| Category | Psychedelics | Psychedelics |
| Status | Schedule I (FDA Breakthrough Therapy for PTSD) | Schedule I (research compound) |
| Mechanism | Triggers large releases of serotonin (and to a lesser extent dopamine and norepinephrine) and increases oxytocin, prolactin and cortisol. This produces feelings of trust, openness and emotional closeness that support psychotherapy. | Directly activates serotonin 5-HT2A receptors. Psilocybin is a "prodrug" that the body converts into psilocin. |
| Molecular weight | 193.25 g/mol | 204.27 g/mol |
| Half-life | ~7-9 hours | ~1-3 hours |
| Bioavailability | Oral, high | Oral |
| Typical dose | 75-125 mg (often with an optional supplemental half-dose) | Varies by individual and setting |
| Frequency | A small number of monthly sessions | Occasional |
| Route | Oral, in a supervised therapeutic setting | Oral |
MDMA reported benefits
- Studied for treatment-resistant PTSD
- Lowers fear response during trauma processing
- Increases trust and emotional openness
- Strong Phase 3 trial results from MAPS
Psilocin reported benefits
- The active form behind psilocybin
- Studied for depression and anxiety
- Faster onset than psilocybin
- Classic serotonergic psychedelic
Related comparisons
Research and educational reference only. Not medical advice.